- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02262260
Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME (SALUTE-D)
A Randomized, Open-label Non-inferiority Study to Compare Safety and Efficacy of Labeled Versus Wait and Extend Regimen of Lucentis (Ranibizumab) in Turkish Patients With Visual Impairment Due to Diabetic Macular Edema.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Adana, Turkey, 01330
- Novartis Investigative Site
-
Ankara, Turkey, 06100
- Novartis Investigative Site
-
Ankara, Turkey, 06500
- Novartis Investigative Site
-
Ankara, Turkey, 06490
- Novartis Investigative Site
-
Ankara, Turkey, 06590
- Novartis Investigative Site
-
Izmir, Turkey, 35040
- Novartis Investigative Site
-
Izmir, Turkey, 35340
- Novartis Investigative Site
-
Kocaeli, Turkey, 41380
- Novartis Investigative Site
-
-
TUR
-
Istanbul, TUR, Turkey, 34098
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent must be obtained before any assessment is performed.
- M or F patients >18 years of age who have signed an informed consent
- Patients with Type 1 or Type 2 DM (according to ADA or WHO guidelines) with HbA1c not more than 12.0% at screening (Visit 1). Patients should be on diet, exercise, and/or pharmacological treatment for diabetes.
- Patients with visual impairment due to focal or diffuse macular edema with center involvement in at least one eye, as demonstrated with color fundus photography, fluorescein angiography and OCT within 28 days of the baseline treatment. If both eyes are eligible, the one with the worse visual acuity, as assessed at Visit 1, will be selected for study treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for study treatment. The study eye must fulfill the following criteria at Visit 1:
- BCVA score between 78 and 39 letters, inclusively, using ETDRS-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160)
- Decrease in vision is due to DME and not due to other causes, in the opinion of the investigator
Exclusion Criteria
- Concomitant conditions in the study eye according to defined criteria such as infection, inflammation, uncontrolled glaucoma
- Active PDR in the study eye or evidence of vitreomacular traction in either eye
- Patients who are monocular or have a BCVA score in the non-study eye (fellow eye) £ 24 letters at Visit 1
- Concomitant systemic condition according to defined criteria, eg. history of stroke, uncontrolled diabetes, renal failure, unsatisfactory controlled hypertension
- Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days until the expected PD effect has returned to baseline, whichever is longer.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.
Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ranibizumab labeled regime arm
Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment).
Thereafter patients should be monitored monthly for visual acuity.
Treatment will be resumed when monitoring indicates loss of visual acuity due to DME.
Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
The interval between two doses should not be shorter than 1 month
|
Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment).
Thereafter patients should be monitored monthly for visual acuity.
Treatment will be resumed when monitoring indicates loss of visual acuity due to DME.
Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
The interval between two doses should not be shorter than 1 month.
Other Names:
|
Experimental: Ranibizumab wait and Extend regime arm
Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later.
If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later.
The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings.
If there is a negative change, the interval is shortened back to 4 weeks.
|
Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later.
If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later.
The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings.
If there is a negative change, the interval is shortened back to 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in "Best-corrected Visual Acuity" at Month 12
Time Frame: 12 months
|
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters.
The range of ETDRS is 0 to 100 letters.
A positive average change from baseline of BCVA indicates improvement
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Central Retinal Thickness (CRT)
Time Frame: 12 months
|
CRT was assessed by Optical Coherence Tomography (OCT).
|
12 months
|
Mean Number of Injections
Time Frame: 12 months
|
Mean number of injections over a 12-month treatment period
|
12 months
|
Mean Number of Visits
Time Frame: 12 months
|
Mean number of visits over a 12-month treatment period
|
12 months
|
Proportion of Patients Who Gained ≥5 Letters
Time Frame: 12 months
|
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
An increased score indicates improvement in acuity.
This outcome assessed the number of participants who had improvement of ≥5 letters of visual acuity at month 12 as compared with baseline
|
12 months
|
Proportion of Patients Who Gained ≥10 Letters
Time Frame: 12 months
|
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
An increased score indicates improvement in acuity.
This outcome assessed the number of participants who had improvement of ≥10 letters of visual acuity at month 12 as compared with baseline
|
12 months
|
Proportion of Patients Who Gained ≥15 Letters
Time Frame: 12 months
|
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
An increased score indicates improvement in acuity.
This outcome assessed the number of participants who had improvement of ≥15 letters of visual acuity at month 12 as compared with baseline
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRFB002DTR01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Labeled regime arm
-
University of LisbonCompletedCardiovascular Diseases | Coronary Artery DiseasePortugal
-
Hasselt UniversityCompleted
-
European University CyprusEden Resort Wellness Rehabilitation CenterRecruiting
-
University of ZurichCompletedGlycogen Storage Disease Type 1 (GSD 1)Switzerland
-
Uppsala UniversityLund UniversityRecruitingChronic Obstructive Pulmonary DiseaseSweden
-
Shanghai Zhongshan HospitalRecruiting
-
Shanghai Zhongshan HospitalShanghai Fifth People's Hospital,Fudan University; XuHui Central Hospital of...Completed
-
Heinrich-Heine University, DuesseldorfCompletedMeibomian Gland DysfunctionGermany
-
Huashan HospitalNot yet recruitingWeight Change, BodyChina
-
Chulalongkorn UniversityUnknown